Health officials in England are weighing a shift to a once‑weekly insulin injection for type 2 diabetes, a move that could slash daily needle use by up to 85 percent.
Weekly option could cut injection burden
The drug, known as insulin efsitora alfa and sold under the brand Onswik, earned a recommendation in draft guidance from the National Institute for Health and Care Excellence (NICE). Evidence reviewed by the agency shows the new schedule matches the blood‑glucose control of the most common daily long‑acting formulations, such as insulin degludec and insulin glargine.
For patients who depend on carers, the reduced schedule may ease daily routines. Those with visual impairment, limited hand strength, learning challenges, or frailty often face hurdles with multiple injections. A single dose each week could mean fewer visits from home‑care teams and a step toward greater independence.
Related: NHS trust adopts voice recognition for surgery
The trial showed similar outcomes, meaning people switching from daily therapy should expect comparable health results while facing far fewer needle sticks. The therapy can be prescribed alone or alongside other medicines that manage type 2 diabetes.
“Moving from daily injections to a single weekly dose could make a real difference to the day‑to‑day lives of people with type 2 diabetes, especially those who rely on a carer, family member or healthcare professional to help them inject,” said Helen Knight, Director of Medicines Evaluation at NICE.
Beyond personal convenience, the change may lessen pressure on community health services. Fewer daily visits translate into lower administration costs, a point that resonates with budget‑conscious NHS planners.
Regulatory steps and potential impact
Before the therapy can be rolled out across the NHS, it must secure licensing from the Medicines and Healthcare products Regulatory Agency (MHRA). If the regulator signs off, the once‑weekly regimen would represent one of the most notable adjustments to insulin delivery in recent years.
Related: St Vincent’s gets new fluoroscopy system
The NHS currently supports roughly 4.6 million diagnosed diabetes cases, with about 90 percent classified as type 2. Demand for diabetes care continues to rise, prompting a search for solutions that keep clinical standards while simplifying treatment.
Patients younger than 40, who juggle work and family, could find the streamlined schedule especially helpful. Simplifying the regimen may also boost adherence for anyone who struggles to keep up with a daily injection timetable.
Under NICE’s draft recommendation, clinicians and patients are urged to discuss all suitable options and choose the most cost‑effective therapy that aligns with individual needs. Factors such as medication price, dosage, administration expenses and personal preference should shape the decision.
